梅雁吉祥(600868.SH):廣東能潤增持計劃完成 累計增持4059.27萬股
格隆匯11月27日丨梅雁吉祥(600868.SH)公佈,公司於2019年11月27日收到公司第一大股東廣東能潤通知,自2019年4月24日-11月27日期間,廣東能潤通過上海證券交易所交易系統累計增持公司股份4059.2683萬股,累計增持金額約為1.41億元,累計增持數量佔公司總股本的2.14%;此次增持已達到增持計劃的下限,並在計劃期限內實施完成。廣東能潤目前持有公司股份1.3550億股,佔公司總股本的7.14%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.